SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership to scale production of its Intelligent Fingerprinting Drug Screening Reader, ahead of its anticipated U.S. market entry and promising significant operational benefits. The community is actively debating its low float and short squeeze potential, with many discussing whether recent price action is a "stop raid" for further upside or a sign of an impending offering.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to its volatile price action as a low-float SPAC, prompting intense community discussion around its potential for a short squeeze or significant gains. Traders are closely watching its 'tiny float' and high insider ownership, drawing parallels to other recent 'shell company rippers' amidst sharp price swings and trading halts. This speculative interest sees many buying dips and holding, anticipating further explosive moves.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing extreme volatility, driven by recent CME margin requirement hikes that many in the community view as manipulation to suppress prices. Amid swirling rumors of Chinese export restrictions on silver, traders are sharply divided between anticipating a massive short squeeze from strong physical demand and expecting a significant pullback in the paper market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is a hot topic, drawing mixed community sentiment regarding its future performance, with many anticipating significant appreciation while others note recent stagnation. Discussions frequently revolve around its foundational role as "digital silver" and the potential for technical indicators to signal a major upward movement. The community is also closely watching broader crypto market trends and Grayscale's influence on LTC's trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following a recent FDA approval of NEREUS, its motion-sickness treatment, marking the first new pharmacologic option in decades. The community is actively discussing the drug's potential expansion into the multi-billion dollar GLP-1 nausea market and views VNDA as a prime takeover target, anticipating further catalysts from its robust pipeline including a February FDA decision for Bysanti.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is currently trending on the Cardano ecosystem as its passionate community, known as the "flock," enthusiastically highlights the token's real-world utility through its CockyWingsLLC fried chicken food truck business and a new MemesHub.io DApp. This meme coin is generating buzz for bringing liquidity on-chain and offering passive income opportunities through its liquid staking "Arena," with many anticipating significant growth into 2026.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is a hot topic as it undergoes a significant corporate restructuring, including discontinuing its lead drug and exploring strategic alternatives like a sale or merger. The immediate catalyst for community conversation is its exceptionally low share float, which is fueling intense speculation about a potential short squeeze. Traders are actively comparing $SNSE to recent parabolic runners, with many anticipating substantial upward momentum despite the company's fundamental changes.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is experiencing renewed interest due to significant institutional developments, including PayPal's stablecoin integration, U.S. Bank's testing of custom stablecoins, and its inclusion in Franklin Templeton's crypto ETF, alongside upcoming network upgrades like Protocol 25. While a segment of the community expresses strong bearish sentiment regarding current price action, others are actively accumulating, bullish on its long-term potential as an ISO 20022 compliant asset. This divergence reflects a battle between immediate price concerns and optimism for XLM's role in the evolving landscape of institutional and cross-border finance.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is highly volatile after the FDA issued a Complete Response Letter for its relacorilant application, seeking additional efficacy evidence despite positive Phase 3 trial data. The market's sharp sell-off is widely viewed by the community as an overreaction, given the company's substantial existing revenue from Korlym, strong cash reserves, and other promising pipeline assets. Investors are now debating the likelihood of a narrower resubmission for relacorilant and the potential for a significant rebound, with many eyeing a temporary bottom.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA has granted priority review to its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, pointing to an accelerated review timeline. This pivotal development, coupled with strong Auvelity sales and anticipated progress toward an NDA for AXS-12 in narcolepsy, is fueling widespread investor optimism. The community is actively discussing Axsome's "best-in-class" pipeline and commercial execution, anticipating significant long-term value appreciation within the CNS therapeutic landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 High-Dividend ETFs to Earn Current Income 

Market looks overheated? Earn stable income with high-dividend ETFs ??? FGD, FDL, IDV, SPYD and DIVO ??? as volatility boosts the appeal of yield.

6 Dividend ETFs Under $50 to Buy Now

Market volatility sparks income hunt -- dividend ETFs like SCHD, CGDV, SPYD, IDV, FDL & DIVO under $50 offer steady yields and value.

<ul class="summary-bullets"><li>Battery electric vehicle sales, however, took a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.&nbsp;</li><li>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.&nbsp;</li><li>The company’s SUV sales, however, fell 4.7% last month to 65,968 units.&nbsp; &nbsp;</li></ul>Ford Motor Co. (F) on Monday said that it delivered 175,584 vehicles in the U.S. in October, marking a growth of 1.6% from the corresponding period last year, thanks to continued demand for its F-series trucks.The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles.<h2 class="st-heading-2">Electric Vehicle Sales Dive</h2>Battery electric vehicle sales, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://s205.q4cdn.com/882619693/files/doc_news/2025/Nov/03/Ford-U-S-October-2025-Sales-Release.pdf">took</a> a sharp hit, decreasing by 24.8% to 4,709 units, likely due to the expiration of the federal tax credit of $7,500 on the purchase of new EVs in the U.S. on September 30.While the company’s Mustang Mach-E sales dived 12.3% to 2,906 units, sales of its EV truck F-150 Lightning dropped 17.2% to 1,543 units. Sales of the company’s electric E-transit van, meanwhile, fell 76.1% to just 260 units.Last month, General Motors announced that it is canceling production of E-transit’s competitor, Brightdrop electric van, in Canada, citing slow development in the commercial electric van market.<h2 class="st-heading-2">F-Series Continues To Reign</h2>The F-series truck continued to be the company’s best-seller in October with 67,930 units sold, marking a growth of 0.7% year-over-year.The company’s SUV sales, however, fell 4.7% last month to 65,968 units, as sales of all of the company’s Lincoln brand SUVs fell, except the Navigator. The retirement of the Ford Edge SUV also weighed on the SUV sales numbers.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/F">F stock</a> is down by 1% at the time of writing. On Stocktwits, retail sentiment around F stock remained within the ‘bearish’ territory, while message volume decreased from ‘normal’ to ‘low’ levels.A Stocktwits user highlighted that November is typically a good month for autos.<stembedurl>https://stocktwits.com/ChumpMoney/message/634683037</stembedurl>F stock is up 31% this year and approximately 25% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-musks-1-trillion-pay-package-to-receive-overwhelming-approval/cL2NOFZR3zw">Gary Black Expects Musk’s $1T Pay Package To Receive ‘Overwhelming’ Approval But Warns Against Optimism On Tesla Robotaxi Expansion Plans</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs reportedly upgraded the stock to ‘Buy’ from ‘Neutral’ and raised its price target to $13 from $12.

Ford Sales In US Rise 1.6% In October On Continued Truck Demand

The growth was primarily driven by a 3.4% growth in sales of the company’s internal combustion engine vehicles. 

Equity

The Zacks Analyst Blog Highlights Invesco QQQ Trust, Palantir, NVIDIA, Home Depot, S&P 500 Pure Value Invesco ETF and Morningstar Dividend Leaders ETF

Tech weakness pressures QQQ, Palantir and NVIDIA, while Home Depot, value ETFs and dividend funds attract investors amid sector rotation.

Time for a Sector Rotation Away from Tech? ETFs in Focus

Tech slump dragged QQQ lower as investors eye rotation into value ETFs like RPV, consumer staples ETFs like IYK, and dividend-focused ETFs like FDL.

Tap 4 Quality ETFs With Cheaper Valuation & Juicy Yields 

Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

Shares of AbbVie Inc. surged 8% on Friday morning, hitting their highest level since early November and lifting retail investor sentiment.&nbsp;The biopharma stock is on track for its best day since March 26, 2020.AbbVie reported fourth-quarter (Q4) adjusted earnings per share (EPS) of $2.16, beating the consensus estimate of $2.12, while revenue came in at $15.1 billion, surpassing expectations of $14.83 billion.&nbsp;CEO Robert Michael highlighted the company’s growth, key regulatory approvals, and strategic transactions, adding, “We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.”Investor sentiment brightened after AbbVie revealed that strong sales of its other immunology drugs — Skyrizi and Rinvoq — as well as newer offerings were offsetting falling Humira revenue.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ABBV_sentiment_and_message_volume_Jan_31_7d4cebfea5.png" alt="ABBV sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>ABBV sentiment and message volume Jan 31 as of 10 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, AbbVie’s sentiment turned ‘extremely bullish’ as message volume spiked, making it one of the platform’s top 10 trending tickers.&nbsp;One user predicted the stock returning to $200, while another pointed to the company’s confidence in differentiating Skyrizi against competitors in 2025.<stembedurl>https://stocktwits.com/Teluride/message/602281004</stembedurl><stembedurl>https://stocktwits.com/BasedPinkWojak/message/602288589</stembedurl>AbbVie reaffirmed expectations for high single-digit compound annual revenue growth through 2029, using 2024 as the base year.&nbsp;It raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025.&nbsp;The company also boosted its 2027 forecast for the two drugs to more than $31 billion, up from a prior estimate of $27 billion, with Skyrizi expected to generate more than $20 billion and Rinvoq over $11 billion.As Humira sales decline, AbbVie has aggressively pursued M&amp;A deals to diversify its pipeline.&nbsp;The stock has gained over 15% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Abbvie Pharma logo seen on screen in the background with pills and a medical vial with syringe, seen in this photo illustration, on 14 August 2023 in Brussels, Belgium. (Photo Illustration by Jonathan Raa/NurPhoto via Getty Images)

AbbVie Stock Nears 3-Month High on Q4 Beat As Immunology Growth Eases Humira Slump: Retail Mood Brightens

The company raised its long-term sales outlook for Skyrizi and Rinvoq, now expecting combined revenue of about $24 billion in 2025. 

FDL
First Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FDL News

FDLFirst Trust Exchange-Traded Fund III - First Trust Morningstar Dividend Leaders Index Fund